Keywords: Bayer, Xarelto, Cardiac event prevention, Ph III, R&D pipeline
Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation
Article | 14 November 2012
German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant Xarelto (rivaroxaban) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
